Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.

IF 2.7
Anton Kravchuk, Julio Ruben Rodas Garzaro, Ralph Wirtz, Ingmar Wolff, Stefan Koch, Thorsten Schlomm, Anja Rabien, Christina Meisl, Dezhi Rong, João Paulo Brás, João Vinagre, Thomas Otto, Dimitri Barski, Andreas Gössl, Stephan Siepmann, Christian Gilfrich, Sabine Brookman-May, Thorsten Ecke, Matthias May
{"title":"Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.","authors":"Anton Kravchuk, Julio Ruben Rodas Garzaro, Ralph Wirtz, Ingmar Wolff, Stefan Koch, Thorsten Schlomm, Anja Rabien, Christina Meisl, Dezhi Rong, João Paulo Brás, João Vinagre, Thomas Otto, Dimitri Barski, Andreas Gössl, Stephan Siepmann, Christian Gilfrich, Sabine Brookman-May, Thorsten Ecke, Matthias May","doi":"10.1016/j.clgc.2026.102554","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Non-invasive urine-based diagnostics for urothelial carcinoma of the bladder remain limited by suboptimal sensitivity. We validated a digital polymerase chain reaction (dPCR) Uromonitor<sup>Ⓡ</sup> assay in a multicentre setting and compared it with an earlier quantitative polymerase chain reaction (qPCR) version and urine cytology.</p><p><strong>Patients and methods: </strong>We analyzed 239 archived urine samples from a prospectively assembled biobank, including 123 patients with histologically confirmed urothelial carcinoma of the bladder and 116 with benign findings. The dPCR panel targeted TERT promoter and FGFR3 hotspot mutations. Historical qPCR data and contemporaneous urine cytology served as comparators. Sensitivity, the prespecified primary endpoint, was compared head to head using McNemar's exact test. Receiver operating characteristic curves with area under the curve (AUC) comparisons and multivariable logistic regression were also performed.</p><p><strong>Results: </strong>dPCR showed higher sensitivity than qPCR and urine cytology (75.6% vs 51.2% and 42.3%, respectively; both p < .001) while maintaining 94.0% specificity. Positive and negative predictive values were 93.0% and 78.4%, respectively, and overall accuracy was 84.5%. The AUC for dPCR was 0.848, exceeding qPCR by 0.122 (p = .001) and urine cytology by 0.188 (p < .001). dPCR positivity was independently associated with histologically confirmed disease (odds ratio 38.9, p < .001). Diagnostic performance remained consistent across grade- and stage-based subgroup analyses.</p><p><strong>Conclusion: </strong>These findings support dPCR as a robust non-invasive diagnostic adjunct under conservative analytical conditions and justify further large-scale prospective multicentre validation in clinically representative populations undergoing bladder cancer surveillance to define its role in risk=adapted evidence-based diagnostic pathways and inform future implementation studies in clinical practice.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102554"},"PeriodicalIF":2.7000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.clgc.2026.102554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Non-invasive urine-based diagnostics for urothelial carcinoma of the bladder remain limited by suboptimal sensitivity. We validated a digital polymerase chain reaction (dPCR) Uromonitor assay in a multicentre setting and compared it with an earlier quantitative polymerase chain reaction (qPCR) version and urine cytology.

Patients and methods: We analyzed 239 archived urine samples from a prospectively assembled biobank, including 123 patients with histologically confirmed urothelial carcinoma of the bladder and 116 with benign findings. The dPCR panel targeted TERT promoter and FGFR3 hotspot mutations. Historical qPCR data and contemporaneous urine cytology served as comparators. Sensitivity, the prespecified primary endpoint, was compared head to head using McNemar's exact test. Receiver operating characteristic curves with area under the curve (AUC) comparisons and multivariable logistic regression were also performed.

Results: dPCR showed higher sensitivity than qPCR and urine cytology (75.6% vs 51.2% and 42.3%, respectively; both p < .001) while maintaining 94.0% specificity. Positive and negative predictive values were 93.0% and 78.4%, respectively, and overall accuracy was 84.5%. The AUC for dPCR was 0.848, exceeding qPCR by 0.122 (p = .001) and urine cytology by 0.188 (p < .001). dPCR positivity was independently associated with histologically confirmed disease (odds ratio 38.9, p < .001). Diagnostic performance remained consistent across grade- and stage-based subgroup analyses.

Conclusion: These findings support dPCR as a robust non-invasive diagnostic adjunct under conservative analytical conditions and justify further large-scale prospective multicentre validation in clinically representative populations undergoing bladder cancer surveillance to define its role in risk=adapted evidence-based diagnostic pathways and inform future implementation studies in clinical practice.

基于数字PCR的尿检用于膀胱癌的分子检测:一项比较定量PCR和尿细胞学的多中心验证研究。
导读:膀胱尿路上皮癌的非侵入性尿液诊断仍然受到灵敏度不佳的限制。我们在多中心环境中验证了数字聚合酶链反应(dPCR) UromonitorⓇ检测,并将其与早期的定量聚合酶链反应(qPCR)版本和尿液细胞学进行了比较。患者和方法:我们分析了来自前瞻性生物库的239份存档尿液样本,包括123例组织学证实的膀胱尿路上皮癌患者和116例良性结果。dPCR小组针对TERT启动子和FGFR3热点突变。历史qPCR数据和同期尿液细胞学作为比较。敏感性,预先指定的主要终点,使用McNemar精确测试进行头与头的比较。受试者工作特征曲线与曲线下面积(AUC)比较和多变量logistic回归。结果:dPCR的敏感性高于qPCR和尿细胞学(分别为75.6%比51.2%和42.3%,p均< 0.001),而特异性保持在94.0%。阳性预测值为93.0%,阴性预测值为78.4%,总体准确率为84.5%。dPCR的AUC为0.848,比qPCR高0.122 (p = .001),比qPCR高0.188 (p < .001)。dPCR阳性与组织学证实的疾病独立相关(优势比38.9,p < 0.001)。诊断表现在分级和分期亚组分析中保持一致。结论:这些发现支持dPCR在保守分析条件下作为一种强大的非侵入性诊断辅助手段,并证明在接受膀胱癌监测的临床代表性人群中进一步进行大规模前瞻性多中心验证,以确定其在风险=适应的循证诊断途径中的作用,并为未来在临床实践中的实施研究提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书